Intrauterine Contraceptive Devices (ICD), also known as Intrauterine Device (IUD) is a device which is a small, T-shaped device that is inserted into a woman’s womb to prevent contraception. The intrauterine contraceptive devices are available as copper ICD and Hormonal ICD.
The Asia-Pacific intrauterine contraceptive device market was valued at $XX million in 2018. The market is anticipated to rise with a CAGR of 4.26%, generating $XX million over the forecast period of 2019-2027.
There are several applications of ICD in the Asia Pacific including, birth control, preventing the endometrial cancer risk such as the risk of developing two primary types of cervical cancer, for instance, the adenosquamous and squamous cell carcinoma, etc., which is expected to further Asia Pacific IUCD market growth over the said forecasting period. Women using the ICD for birth control are expected to have minimal risk of cervical cancer as compared to those having no history of ICD usage.
China is expected to be a significant revenue contributor to this market. The Chinese market is chiefly being driven by the various awareness initiatives undertaken by the schools and other educational institutions regarding the benefits of IUD to avoid unwanted teen pregnancy.
DKT International, Krishco Medical Products Pvt. Ltd., Medisafe Distribution Inc., Meril Life Sciences Pvt. Ltd., Melbea, Egemen International, Merck & Co., Mona Lisa N.V., OCON Medical Ltd., Trimedic Supply Network Ltd., Medicines360, Bayers AG, Pregna, HLL LifeCare Ltd., SMB Corporation, Zhejiang Daji Medical Instruments Co., Ltd., Okamoto Industries Inc., Allergan PLC, Teva Pharmaceutical Industries Limited, and Pfizer are some of the noted companies in the region which have been extensively profiled in the report.